This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
This randomized trial compared chemoradiotherapy alone to chemoradiotherapy followed by consolidation therapy with the PDL-1 antibody durvalumab in patients with stage III NSCLC. The treatment group had significantly improved progression-free survival, response rate, and overall survival, with clinically meaningful differences between the groups. The findings suggest that such regimens may be the new standard of care in these patients.